

Andrew W Roberts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5908906/publications.pdf>

Version: 2024-02-01

236
papers

25,474
citations

11235

73
h-index

8034

154
g-index

238
all docs

238
docs citations

238
times ranked

26915
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal hematopoiesis, myeloid disorders and <i>BAX</i> -mutated myelopoiesis in patients receiving venetoclax for CLL. <i>Blood</i> , 2022, 139, 1198-1207.	0.6	34
2	Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. <i>Blood Advances</i> , 2022, 6, 1296-1308.	2.5	42
3	Single-cell sequencing demonstrates complex resistance landscape in Δ CLL and MCL treated with BTK and BCL2 inhibitors. <i>Blood Advances</i> , 2022, 6, 503-508.	2.5	16
4	Acute leukaemia in Australia: outcomes have improved, but there is still much to do. <i>Medical Journal of Australia</i> , 2022, 216, 289-290.	0.8	0
5	Germline MBD4 deficiency causes a multi-tumor predisposition syndrome. <i>American Journal of Human Genetics</i> , 2022, 109, 953-960.	2.6	23
6	Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy. <i>Blood</i> , 2022, 140, 2127-2141.	0.6	28
7	Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy. <i>EJHaem</i> , 2021, 2, 266-271.	0.4	3
8	Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. <i>Blood</i> , 2021, 137, 2721-2735.	0.6	75
9	Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. <i>Blood</i> , 2021, 138, 836-846.	0.6	27
10	Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. <i>Clinical Cancer Research</i> , 2021, 27, 4690-4695.	3.2	38
11	BCL2 and MCL1 inhibitors for hematologic malignancies. <i>Blood</i> , 2021, 138, 1120-1136.	0.6	78
12	Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies. <i>Blood</i> , 2021, 138, 1089-1089.	0.6	0
13	Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). <i>Leukemia and Lymphoma</i> , 2021, 62, 2981-2991.	0.6	2
14	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. <i>Blood Advances</i> , 2021, 5, 4054-4058.	2.5	39
15	Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing. <i>Genome Biology</i> , 2021, 22, 310.	3.8	83
16	Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma. <i>Haematologica</i> , 2020, 105, e76-e79.	1.7	37
17	Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation. <i>Nature Immunology</i> , 2020, 21, 54-64.	7.0	33
18	Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. <i>Oncogene</i> , 2020, 39, 2009-2023.	2.6	16

#	ARTICLE	IF	CITATIONS
19	Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. <i>Blood Advances</i> , 2020, 4, 4849-4859.	2.5	14
20	Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3506-3517.	0.8	112
21	Therapeutic development and current uses of BCL-2 inhibition. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 1-9.	0.9	66
22	Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. <i>Blood</i> , 2020, 136, 2027-2037.	0.6	78
23	Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. <i>Blood Advances</i> , 2020, 4, 2762-2767.	2.5	28
24	Targeting MCL-1 in hematologic malignancies: Rationale and progress. <i>Blood Reviews</i> , 2020, 44, 100672.	2.8	135
25	Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells. <i>Cell Death and Differentiation</i> , 2020, 27, 2217-2233.	5.0	29
26	Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. <i>Blood</i> , 2020, 135, 773-777.	0.6	115
27	Changing of the guard—the old and the new. <i>Blood</i> , 2020, 135, 1-1.	0.6	1
28	Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. <i>Blood Advances</i> , 2020, 4, 165-173.	2.5	34
29	Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 7-8.	0.6	13
30	BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 9-10.	0.6	4
31	The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16). <i>Blood</i> , 2020, 136, 16-18.	0.6	3
32	BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. <i>Blood</i> , 2020, 135, 2266-2270.	0.6	67
33	High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 15-16.	0.6	2
34	Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?. <i>Cancer Discovery</i> , 2019, 9, 998-1000.	7.7	5
35	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. <i>Blood</i> , 2019, 134, 851-859.	0.6	259
36	Venetoclax in Lymphoid Malignancies: New Insights, More to Learn. <i>Cancer Cell</i> , 2019, 36, 341-343.	7.7	19

#	ARTICLE	IF	CITATIONS
37	A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e53-e54.	0.2	19
38	Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 186, e188-e191.	1.2	37
39	Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. <i>Nature Communications</i> , 2019, 10, 2385.	5.8	139
40	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. <i>Blood</i> , 2019, 134, 111-122.	0.6	145
41	Venetoclax for the treatment of mantle cell lymphoma. <i>Annals of Lymphoma</i> , 2019, 3, 4-4.	4.5	1
42	Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 905-917.	3.3	126
43	A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2019, 9, 354-369.	7.7	104
44	Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. <i>Nature Medicine</i> , 2019, 25, 119-129.	15.2	147
45	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. <i>Cancer Discovery</i> , 2019, 9, 342-353.	7.7	306
46	BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib. <i>Blood</i> , 2019, 134, 170-170.	0.6	33
47	Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. <i>Blood</i> , 2019, 134, 756-756.	0.6	24
48	Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study. <i>Blood</i> , 2019, 134, 462-462.	0.6	5
49	Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study. <i>Blood</i> , 2019, 134, 3999-3999.	0.6	6
50	Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting. <i>Internal Medicine Journal</i> , 2018, 48, 786-794.	0.5	6
51	Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. <i>Leukemia</i> , 2018, 32, 1034-1037.	3.3	56
52	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1211-1223.	13.9	343
53	Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. <i>Leukemia</i> , 2018, 32, 303-312.	3.3	123
54	Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3525-3527.	0.8	22

#	ARTICLE	IF	CITATIONS
55	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1973-1980.	0.8	257
56	BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. <i>Cancer Cell</i> , 2018, 34, 879-891.	7.7	250
57	AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. <i>Cancer Discovery</i> , 2018, 8, 1582-1597.	7.7	310
58	BCL2 Inhibitors: Insights into Resistance. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 23-43.	0.1	0
59	MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML. <i>Blood</i> , 2018, 132, 1526-1534.	0.6	90
60	Statins enhance efficacy of venetoclax in blood cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	61
61	Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 4371-4379.	3.2	127
62	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, LBA-7-LBA-7.	0.6	6
63	Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab. <i>Blood</i> , 2018, 132, 183-183.	0.6	5
64	Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study). <i>Blood</i> , 2018, 132, 333-333.	0.6	14
65	Abstract 1366:MBD4guards against DNA damage from methylcytosine deamination. , 2018, , .		0
66	Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2017, 47, 35-49.	0.5	10
67	Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 4527-4533.	3.2	56
68	Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. <i>Lancet Oncology</i> , The, 2017, 18, 230-240.	5.1	287
69	Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. <i>Blood</i> , 2017, 129, 3362-3370.	0.6	150
70	Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. <i>Blood</i> , 2017, 130, 2392-2400.	0.6	229
71	Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. <i>Internal Medicine Journal</i> , 2017, 47, 938-951.	0.5	19
72	Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 89-98.	2.3	107

#	ARTICLE	IF	CITATIONS
73	Venetoclax: a primer. <i>Blood Advances</i> , 2017, 1, 467-467.	2.5	17
74	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 826-833.	0.8	596
75	Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 1678-1685.	0.8	14
76	Rapid Inflammation in Mice Lacking Both SOCS1 and SOCS3 in Hematopoietic Cells. <i>PLoS ONE</i> , 2016, 11, e0162111.	1.1	24
77	Nephrotic syndrome as a complication of chronic graft-versus-host disease after allogeneic haemopoietic stem cell transplantation. <i>Internal Medicine Journal</i> , 2016, 46, 737-741.	0.5	16
78	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 768-778.	5.1	676
79	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. <i>Blood</i> , 2016, 127, 3215-3224.	0.6	242
80	Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. <i>Blood</i> , 2016, 128, 1834-1844.	0.6	127
81	Targeting BCL-2-like Proteins to Kill Cancer Cells. <i>Trends in Cancer</i> , 2016, 2, 443-460.	3.8	114
82	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. <i>Blood</i> , 2016, 128, 1382-1395.	0.6	148
83	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. <i>Nature</i> , 2016, 538, 477-482.	13.7	830
84	Targeting GM-CSF in inflammatory diseases. <i>Nature Reviews Rheumatology</i> , 2016, 12, 37-48.	3.5	217
85	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 311-322.	13.9	1,532
86	BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. <i>Leukemia</i> , 2016, 30, 1531-1541.	3.3	29
87	Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2016, 43, 274-279.	0.8	17
88	Current challenges and novel treatment strategies in double hit lymphomas. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 52-64.	1.1	20
89	Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 2033-2033.	0.6	6
90	Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 3230-3230.	0.6	12

#	ARTICLE	IF	CITATIONS
91	Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4395-4395.	0.6	7
92	Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 975-975.	0.6	20
93	Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival. <i>Blood</i> , 2016, 128, 338-338.	0.6	0
94	Targeting apoptotic pathways to treat lymphoid malignancies. <i>Rinsho Ketsueki/the Japanese Journal of Clinical Hematology</i> , 2016, 57, 2054-2058.	0.5	1
95	Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. <i>Blood</i> , 2015, 125, 2649-2655.	0.6	107
96	Validating the Allogeneic Stem Cell Transplantation Disease Risk Index. <i>Transplantation</i> , 2015, 99, 128-132.	0.5	10
97	Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1 β . <i>Journal of Experimental Medicine</i> , 2015, 212, 927-938.	4.2	120
98	BCL2 inhibition in double hit lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1928-1929.	0.6	1
99	Donald Metcalf (1929-2014). <i>Cell</i> , 2015, 160, 361-362.	13.5	2
100	Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2015, 45, 94-105.	0.5	13
101	Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2015, 45, 371-382.	0.5	19
102	Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 5222-5234.	3.2	4
103	Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2015, 45, 335-343.	0.5	6
104	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20 ⁺ lymphoid malignancies. <i>British Journal of Haematology</i> , 2015, 170, 669-678.	1.2	80
105	A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 1406-1415.	0.6	111
106	Fas regulates neutrophil lifespan during viral and bacterial infection. <i>Journal of Leukocyte Biology</i> , 2015, 97, 321-326.	1.5	28
107	A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 254-254.	0.6	61
108	Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 2939-2939.	0.6	10

#	ARTICLE	IF	CITATIONS
109	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results. <i>Blood</i> , 2015, 126, 3038-3038.	0.6	16
110	Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study. <i>Blood</i> , 2015, 126, 830-830.	0.6	38
111	The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial. <i>Blood</i> , 2015, 126, 832-832.	0.6	90
112	Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study. <i>Blood</i> , 2015, 126, LBA-6-LBA-6.	0.6	13
113	Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1 β . <i>Journal of Cell Biology</i> , 2015, 209, 2095OIA104.	2.3	0
114	Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study. <i>Lancet Haematology</i> , 2014, 1, e112-e119.	2.2	8
115	Targeting BCL2 for the Treatment of Lymphoid Malignancies. <i>Seminars in Hematology</i> , 2014, 51, 219-227.	1.8	130
116	RIPK1 Regulates RIPK3-MLKL-Driven Systemic Inflammation and Emergency Hematopoiesis. <i>Cell</i> , 2014, 157, 1175-1188.	13.5	492
117	Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. <i>Leukemia</i> , 2014, 28, 2213-2221.	3.3	122
118	Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. <i>Leukemia</i> , 2014, 28, 1207-1215.	3.3	79
119	First-in Man, Phase 1 Study of CSL362 (Anti-IL3R α / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse. <i>Blood</i> , 2014, 124, 120-120.	0.6	50
120	Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 325-325.	0.6	32
121	Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments. <i>Blood</i> , 2014, 124, 2103-2103.	0.6	0
122	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. <i>Nature Medicine</i> , 2013, 19, 202-208.	15.2	2,426
123	BH3 mimetic therapy: an emerging and promising approach to treating chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 909-911.	0.6	2
124	GFI1B mutation causes a bleeding disorder with abnormal platelet function. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 2039-2047.	1.9	91
125	Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2599-2604.	3.3	43
126	The genomic landscape of hypodiploid acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013, 45, 242-252.	9.4	588

#	ARTICLE	IF	CITATIONS
127	Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263). <i>Blood</i> , 2013, 121, 1479-1481.	0.6	20
128	Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis. <i>Blood</i> , 2013, 122, 108-108.	0.6	31
129	Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction. <i>Blood</i> , 2013, 122, 1304-1304.	0.6	10
130	The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients. <i>Blood</i> , 2013, 122, 1789-1789.	0.6	32
131	Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study. <i>Blood</i> , 2013, 122, 537-537.	0.6	5
132	Necroptotic Death Of RIPK1-Deficient HSC Compromises Hematopoiesis. <i>Blood</i> , 2013, 122, 218-218.	0.6	0
133	Single-Centre Validation Of a Disease Risk Index For Estimating Survival and Relapse In Allogeneic Hematopoietic Stem Cell Transplant Recipients: Sample Size, Adequate Follow-Up, and Use Of Local Data Are Vital Considerations. <i>Blood</i> , 2013, 122, 2143-2143.	0.6	0
134	The equivalents of human blood and spleen dendritic cell subtypes can be generated in vitro from human CD34+ stem cells in the presence of fms-like tyrosine kinase 3 ligand and thrombopoietin. <i>Cellular and Molecular Immunology</i> , 2012, 9, 446-454.	4.8	59
135	Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. <i>Cell Death and Disease</i> , 2012, 3, e409-e409.	2.7	42
136	Mcl-1 and Bcl-xL coordinately regulate megakaryocyte survival. <i>Blood</i> , 2012, 119, 5850-5858.	0.6	76
137	IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3. <i>Immunology and Cell Biology</i> , 2012, 90, 124-129.	1.0	41
138	Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. <i>Blood</i> , 2012, 119, 5807-5816.	0.6	168
139	Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. <i>Journal of Clinical Oncology</i> , 2012, 30, 488-496.	0.8	719
140	Towards a Four-Dimensional View of Neutrophils. <i>Methods in Molecular Biology</i> , 2012, 844, 87-99.	0.4	6
141	Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis. <i>Blood</i> , 2012, 120, 178-178.	0.6	13
142	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. <i>Blood</i> , 2012, 120, 304-304.	0.6	18
143	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study. <i>Blood</i> , 2012, 120, 3923-3923.	0.6	3
144	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. <i>Journal of Experimental Medicine</i> , 2011, 208, 2017-2031.	4.2	162

#	ARTICLE	IF	CITATIONS
145	Bcl-xL inhibitory BH3 mimetics can induce a transient thrombocytopenia that undermines the hemostatic function of platelets. <i>Blood</i> , 2011, 118, 1663-1674.	0.6	262
146	Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. <i>Pathology</i> , 2011, 43, 525-535.	0.3	36
147	Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 13135-13140.	3.3	98
148	Neutrophils Require SHP1 To Regulate IL-1 β Production and Prevent Inflammatory Skin Disease. <i>Journal of Immunology</i> , 2011, 186, 1131-1139.	0.4	40
149	Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, in Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis. <i>Blood</i> , 2011, 118, 282-282.	0.6	54
150	An Expanded Multicenter Phase I/II Study of CYT387, a JAK-1/2 Inhibitor for the Treatment of Myelofibrosis. <i>Blood</i> , 2011, 118, 3849-3849.	0.6	16
151	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. <i>Journal of Cell Biology</i> , 2011, 194, i12-i12.	2.3	0
152	SOCS3 regulates graft-versus-host disease. <i>Blood</i> , 2010, 116, 287-296.	0.6	37
153	Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. <i>British Journal of Haematology</i> , 2010, 150, 39-45.	1.2	72
154	Regulation of interleukin-1 β by interferon- β is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production. <i>EMBO Reports</i> , 2010, 11, 640-646.	2.0	72
155	The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic In Vitro and in Vivo Interactions with Established Drugs. <i>Molecular Pharmacology</i> , 2010, 77, 483-494.	1.0	111
156	Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 16625-16630.	3.3	37
157	Structural Basis for Apoptosis Inhibition by Epstein-Barr Virus BHRF1. <i>PLoS Pathogens</i> , 2010, 6, e1001236.	2.1	99
158	Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study in Patients with CD20-Positive Lymphoid Malignancies. <i>Blood</i> , 2010, 116, 3943-3943.	0.6	3
159	Reply to M. Cavo. <i>Journal of Clinical Oncology</i> , 2009, 27, e188-e188.	0.8	0
160	Regulation of multiple cytokine signalling pathways by SOCS3 is independent of SOCS2. <i>Growth Factors</i> , 2009, 27, 384-393.	0.5	18
161	Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 714-722.	3.2	27
162	The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. <i>Leukemia</i> , 2009, 23, 2034-2041.	3.3	91

#	ARTICLE	IF	CITATIONS
163	Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure. <i>Journal of Clinical Oncology</i> , 2009, 27, 1788-1793.	0.8	315
164	BH3-mimetics – the solution to chemoresistance?. <i>Leukemia and Lymphoma</i> , 2009, 50, 1069-1072.	0.6	4
165	Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. <i>Blood</i> , 2009, 114, 663-666.	0.6	274
166	Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). <i>Blood</i> , 2009, 113, 4819-4820.	0.6	51
167	Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants. <i>Bone Marrow Transplantation</i> , 2008, 41, 651-658.	1.3	17
168	Socs3 maintains the specificity of biological responses to cytokine signals during granulocyte and macrophage differentiation. <i>Experimental Hematology</i> , 2008, 36, 786-798.	0.2	28
169	Perturbed thymopoiesis in vitro in the absence of suppressor of cytokine signalling 1 and 3. <i>Molecular Immunology</i> , 2008, 45, 2888-2896.	1.0	9
170	In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17961-17966.	3.3	137
171	Bortezomib: Putting mantle cell lymphoma on death row. <i>Leukemia and Lymphoma</i> , 2008, 49, 657-658.	0.6	5
172	A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis. <i>Blood</i> , 2008, 112, 5193-5201.	0.6	141
173	Complete Remission on 18F-FDG-PET Prior to Autologous Stem Cell Transplantation Predicts Superior Event Free Survival of Patients with Relapsed or Refractory Hodgkin Lymphoma.. <i>Blood</i> , 2008, 112, 2188-2188.	0.6	0
174	Mechanism of crosstalk inhibition of IL-6 signaling in response to LPS and TNF α . <i>Growth Factors</i> , 2007, 25, 319-328.	0.5	13
175	Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. <i>Blood</i> , 2007, 109, 2380-2388.	0.6	73
176	The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. <i>Blood</i> , 2007, 110, 1466-1474.	0.6	57
177	A Prospective Multicenter Trial of Peripheral Blood Stem Cell Sibling Allografts for Acute Myeloid Leukemia in First Complete Remission Using Fludarabine-Cyclophosphamide Reduced Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 560-567.	2.0	24
178	Programmed Anuclear Cell Death Delimits Platelet Life Span. <i>Cell</i> , 2007, 128, 1173-1186.	13.5	910
179	Graft-versus-lymphoma effect in progressive hepatosplenic gamma/delta T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1448-1450.	0.6	13
180	A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2007, 40, 157-163.	1.3	29

#	ARTICLE	IF	CITATIONS
181	Improved Relapse Free Survival Is Predicted by a Negative Pre-Transplant FDG-PET Scan Following Salvage Chemotherapy for Relapsed Diffuse Large B Cell Lymphoma (DLBCL) Treated with Autologous Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 5115-5115.	0.6	0
182	Granulocyte colony-stimulating factor and neutrophilsâ€™forgotten mediators of inflammatory disease. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 500-510.	3.2	161
183	Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated G-CSF. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 603-607.	2.0	40
184	Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. <i>Pathology</i> , 2006, 38, 336-342.	0.3	14
185	More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders. <i>Blood</i> , 2006, 107, 1733-1735.	0.6	10
186	Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders. <i>Bone Marrow Transplantation</i> , 2006, 37, 923-928.	1.3	20
187	Absence of Suppressor of Cytokine Signalling 3 Reduces Self-Renewal and Promotes Differentiation in Murine Embryonic Stem Cells. <i>Stem Cells</i> , 2006, 24, 604-614.	1.4	51
188	The hyper-CVADâ€™rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. <i>Annals of Hematology</i> , 2006, 86, 101-105.	0.8	63
189	The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. <i>Cancer Cell</i> , 2006, 10, 389-399.	7.7	1,149
190	Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 14907-14912.	3.3	310
191	Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 16442-16447.	3.3	76
192	SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. <i>Journal of Clinical Investigation</i> , 2006, 116, 1571-1581.	3.9	184
193	First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) Trial of Thalidomide and Alternate Day Prednisolone Following Autologous Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (ALLG MM6).. <i>Blood</i> , 2006, 108, 58-58.	0.6	22
194	The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis. <i>Blood</i> , 2005, 105, 3512-3520.	0.6	74
195	A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2005, 11, 5504-5514.	3.2	50
196	Genetic reduction of embryonic leukemia-inhibitory factor production rescues placentation in SOCS3-null embryos but does not prevent inflammatory disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 16333-16338.	3.3	45
197	G-CSF: A key regulator of neutrophil production, but that's not all!. <i>Growth Factors</i> , 2005, 23, 33-41.	0.5	301
198	Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated-G-CSF.. <i>Blood</i> , 2005, 106, 1970-1970.	0.6	0

#	ARTICLE	IF	CITATIONS
199	A Pilot Study To Explore the Tolerability and Efficacy of Thalidomide Containing Regimens To Reduce Tumour Cell Load Prior to HSC in Multiple Myeloma and the Feasibility of Harvesting HSC Following Thalidomide Containing Regimens.. Blood, 2005, 106, 5162-5162.	0.6	0
200	From The Cover: Suppressor screen in Mpl ^{-/-} mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6553-6558.	3.3	178
201	Critical role for granulocyte colony-stimulating factor in inflammatory arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11398-11403.	3.3	119
202	Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Internal Medicine Journal, 2004, 34, 192-200.	0.5	46
203	Staged autologous peripheral blood progenitor cell transplantation for Ewing sarcoma and rhabdomyosarcoma. Internal Medicine Journal, 2004, 34, 431-434.	0.5	7
204	A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation. Bone Marrow Transplantation, 2004, 34, 447-453.	1.3	20
205	SOCS3 Is a Critical Physiological Negative Regulator of G-CSF Signaling and Emergency Granulopoiesis. Immunity, 2004, 20, 153-165.	6.6	257
206	Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip.. Blood, 2004, 104, 2253-2253.	0.6	6
207	Tissue Iron Overload Is Common Post Transplantation (Allo BMT) and Is Associated with Red Cell Transfusion Load and HFE Genotype.. Blood, 2004, 104, 2262-2262.	0.6	0
208	Abnormal neutrophil phenotype and neutrophil FcR111 deficiency corrected by bone marrow transplantation. Transfusion, 2003, 35, 874-878.	0.8	2
209	Morphological effects of imatinib mesylate (ST1571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia. International Journal of Laboratory Hematology, 2003, 25, 119-125.	0.2	7
210	SOCS3 negatively regulates IL-6 signaling in vivo. Nature Immunology, 2003, 4, 540-545.	7.0	743
211	Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. Biology of Blood and Marrow Transplantation, 2003, 9, 435-442.	2.0	22
212	Dok-related protein negatively regulates T cell development via its RasGTPase-activating protein and Nck docking sites. Journal of Cell Biology, 2002, 158, 115-125.	2.3	33
213	The Rac2 Guanosine Triphosphatase Regulates B Lymphocyte Antigen Receptor Responses and Chemotaxis and Is Required for Establishment of B-1a and Marginal Zone B Lymphocytes. Journal of Immunology, 2002, 168, 3376-3386.	0.4	115
214	Successful Allogeneic Stem Cell Transplant after Invasive Pulmonary Zygomycosis. Leukemia and Lymphoma, 2002, 43, 437-439.	0.6	16
215	Hematopoietic abnormalities in mice deficient in gp130-mediated STAT signaling. Experimental Hematology, 2002, 30, 1248-1256.	0.2	25
216	Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy. British Journal of Haematology, 2002, 119, 204-211.	1.2	9

#	ARTICLE	IF	CITATIONS
217	Rac2-deficient mice display perturbed T-cell distribution and chemotaxis, but only minor abnormalities in T H 1 responses. <i>Immunology and Cell Biology</i> , 2002, 80, 231-240.	1.0	52
218	A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002, 30, 645-650.	1.3	8
219	Acute left ventricular failure following melphalan and fludarabine conditioning. <i>Bone Marrow Transplantation</i> , 2001, 28, 101-103.	1.3	58
220	Rac and Cdc42 GTPases control hematopoietic stem cell shape, adhesion, migration, and mobilization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 5614-5618.	3.3	182
221	Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 9324-9329.	3.3	288
222	Identification of a genetic locus modulating splenomegaly induced by granulocyte colony-stimulating factor in mice. <i>Leukemia</i> , 2000, 14, 657-661.	3.3	16
223	Role of the Guanosine Triphosphatase Rac2 in T Helper 1 Cell Differentiation. <i>Science</i> , 2000, 288, 2219-2222.	6.0	151
224	Mini-allografts™ for haematological malignancies: an alternative to conventional myeloablative marrow transplantation. <i>Australian and New Zealand Journal of Medicine</i> , 1999, 29, 308-314.	0.5	12
225	Deficiency of the Hematopoietic Cell-Specific Rho Family GTPase Rac2 Is Characterized by Abnormalities in Neutrophil Function and Host Defense. <i>Immunity</i> , 1999, 10, 183-196.	6.6	513
226	Cytokine Production and Function in c-mpl-deficient Mice: No Physiologic Role for Interleukin-3 in Residual Megakaryocyte and Platelet Production. <i>Blood</i> , 1998, 91, 2745-2752.	0.6	62
227	Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 1195-1200.	3.3	347
228	Optimal Regimens for the Mobilization and Collection of Peripheral Blood Progenitor Cells from Normal Donors. <i>Leukemia and Lymphoma</i> , 1997, 27, 77-82.	0.6	0
229	Genetic Influences Determining Progenitor Cell Mobilization and Leukocytosis Induced by Granulocyte Colony-Stimulating Factor. <i>Blood</i> , 1997, 89, 2736-2744.	0.6	140
230	Mouse loci for malaria-induced mortality and the control of parasitaemia. <i>Nature Genetics</i> , 1997, 17, 380-381.	9.4	98
231	Studies of the c-Mpl Thrombopoietin Receptor through Gene Disruption and Activation. <i>Stem Cells</i> , 1996, 14, 124-132.	1.4	33
232	Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. <i>Stem Cells</i> , 1995, 13, 512-516.	1.4	68
233	Phase II study of glycosylated recombinant human granulocyte colony-stimulating factor after HLA-identical sibling bone marrow transplantation. <i>Australian and New Zealand Journal of Medicine</i> , 1994, 24, 541-546.	0.5	4
234	Immune thrombocytopenia complicating pulmonary tuberculosis: case report and investigation of mechanisms. <i>Thorax</i> , 1992, 47, 396-397.	2.7	32

#	ARTICLE	IF	CITATIONS
235	Allâ€trans retinoic acid â€“ chemotherapy interactions in acute promyelocytic leukaemia. Australian and New Zealand Journal of Medicine, 1992, 22, 704-704.	0.5	0
236	The Diagnosis of Abdominal Aortic Aneurysms1. ANZ Journal of Surgery, 1974, 44, 360-362.	0.3	3